Oncology & Cancer

Bevacizumab doesn't prolong survival in stage II-III colon CA

(HealthDay)—For patients with stage 2 to 3 colon cancer, the addition of bevacizumab to modified fluorouracil, leucovorin, and oxaliplatin (FOLFOX6) does not prolong disease-free or overall survival, according to a study ...

Oncology & Cancer

Chemo may extend survival after breast cancer's return

(HealthDay)—In women with breast cancer that has recurred but remains confined to in or near the breast, post-surgical chemotherapy appears to boost survival, new research shows.

Oncology & Cancer

Study links age, insurance, but not race, to chemo rates

(HealthDay) -- For women with breast cancer, disease characteristics correlate significantly with chemotherapy receipt, with no indication of racial barriers to treatment, according to a study published online Aug. 6 in the ...

Oncology & Cancer

Chemo-Linked factors may impact weight in breast cancer

(HealthDay) -- Adjuvant chemotherapy for early-stage breast cancer can induce weight gain and a variety of metabolic changes that may be associated with a poor prognosis for some patients, according to research published ...

Oncology & Cancer

Complementary meds used by 17 percent of elderly with cancer

(HealthDay) -- The prevalence of older people with cancer using complementary medications as they start a chemotherapy regimen is 17 percent, and is associated with less advanced disease and higher functional status, according ...

page 9 from 10